MA59115A1 - Camptothecin analogues conjugated to a glutamine residue in a protein and their use - Google Patents
Camptothecin analogues conjugated to a glutamine residue in a protein and their useInfo
- Publication number
- MA59115A1 MA59115A1 MA59115A MA59115A MA59115A1 MA 59115 A1 MA59115 A1 MA 59115A1 MA 59115 A MA59115 A MA 59115A MA 59115 A MA59115 A MA 59115A MA 59115 A1 MA59115 A1 MA 59115A1
- Authority
- MA
- Morocco
- Prior art keywords
- protein
- glutamine residue
- camptothecin
- drug conjugates
- camptothecin analogues
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne des conjugués protéine-médicament et des compositions de ceux-ci qui sont utiles, par exemple, pour administrer spécifiquement à une cible des fractions thérapeutiques, par exemple des analogues de camptothécine et/ou des dérivés. Dans certains modes de réalisation, l'invention concerne des procédés spécifiques et efficaces pour produire des constructions protéine-médicament (par exemple, des conjugués anticorps-médicament) à l'aide d'une combinaison de transglutaminase et de techniques de 1,3-cycloaddition. L'invention concerne des analogues de camptothécine, des conjugués anticorps-médicament, ainsi que des compositions qui contiennent des anticorps modifiés par glutaminyle et des charges utiles analogues de camptothécine.Disclosed herein are protein-drug conjugates and compositions thereof which are useful, for example, for target-specific delivery of therapeutic moieties, eg, camptothecin analogs and/or derivatives. In certain embodiments, the invention relates to specific and efficient methods for producing protein-drug constructs (eg, antibody-drug conjugates) using a combination of transglutaminase and 1,3- cycloaddition. Disclosed are camptothecin analogs, antibody-drug conjugates, and compositions that contain glutaminyl-modified antibodies and camptothecin analog payloads.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063051172P | 2020-07-13 | 2020-07-13 | |
PCT/US2021/041304 WO2022015656A1 (en) | 2020-07-13 | 2021-07-12 | Camptothecin analogs conjugated to a glutamine residue in a protein, and their use |
Publications (1)
Publication Number | Publication Date |
---|---|
MA59115A1 true MA59115A1 (en) | 2023-03-31 |
Family
ID=85793881
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA59115A MA59115A1 (en) | 2020-07-13 | 2021-07-12 | Camptothecin analogues conjugated to a glutamine residue in a protein and their use |
Country Status (1)
Country | Link |
---|---|
MA (1) | MA59115A1 (en) |
-
2021
- 2021-07-12 MA MA59115A patent/MA59115A1/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2024003180A (en) | Camptothecin analogs conjugated to a glutamine residue in a protein, and their use. | |
MA45280B1 (en) | Eribulin-based antibody-drug conjugates and methods of use thereof | |
MA31519B1 (en) | LYOPHILIZED IMMUNOGLOBULIN COMPOSITIONS AND METHODS OF PREPARATION | |
CA1336496C (en) | Immunoconjugates joined by thioether bonds having reduced toxicity and improved selectivity | |
MA28784B1 (en) | ANTI-HER2 ANTIBODY COMPOSITION | |
ES2440482T3 (en) | PSMA-antibody-drug conjugates | |
EA202091135A1 (en) | HYDROPHILIC LINKERS FOR ANTI-BODY-DRUG CONJUGATE CONJUGATES | |
MA31617B1 (en) | CYTOTOXIC AGENTS COMPRISING NOVEL TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE. | |
CO4940469A1 (en) | ORAL COMPOSITION OF IMPROVED STABILITY INCLUDING A DERIVATIVE OF INDOLINONE AND A MIXTURE OF GLYCERIDES OR POLYETHYLENE GLYCOL ESTERS | |
LU93067I2 (en) | BLINATUMOMAB AND ITS PHARMACEUTICALLY ACCEPTABLE DERIVATIVES (BLINCYTO) | |
BRPI0309868B1 (en) | methods of preparing a lower conjugated fraction composition | |
JP2020534030A5 (en) | ||
ATE64396T1 (en) | CONJUGATED VINBLASTIN COMPOUNDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | |
MA50259A1 (en) | Steroids and their antibody conjugates | |
DE69737867D1 (en) | TARGETED COMBINATION IMMUNOTHERAPY FOR CANCER | |
EP1594542A4 (en) | Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders | |
BR0116464A (en) | ether starch substituted imidazoquinolines | |
DE60138222D1 (en) | MODULATION OF IL-2 AND IL-15 MEDIATED T ZONE LANGUAGES | |
BR0011448A (en) | Amide Substituted Imidazoquinolines | |
HUP0101343A2 (en) | Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with prostaglandin inhibitor | |
BR0109846A (en) | Use of a composition comprising an antibody or antigen binding fragment thereof, and together | |
MA27052A1 (en) | PHARMACEUTICAL COMPOSITIONS OF AMLODIPINE AND ATORVASTATIN | |
NZ762865A (en) | Psma-targeting amanitin conjugates | |
PL2161283T3 (en) | Compositions comprising antibodies against CD79b conjugated to a growth inhibitory agent or cytotoxic agent and methods for the treatment of tumor of hematopoietic origin | |
MA59115A1 (en) | Camptothecin analogues conjugated to a glutamine residue in a protein and their use |